



PRESS RELEASE

Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)

SAN DIEGO – Nov. 5, 2018 - Samumed, LLC, announced today that it will present clinical and preclinical data on the company’s small molecule Wnt pathway inhibitor, SM04690, in four poster presentations at the 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD) in Bangkok, Thailand, November 8-10, 2018.

“We look forward to sharing these data, which all support SM04690 as a potential disease-modifying osteoarthritis drug, with the BMJD community,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed.

Samumed’s posters will be available for viewing during the congress from Friday, November 9, through the end of sessions on Saturday, November 10. Poster presentation details:

Abstract Title	Poster Number
Joint space width criteria can reduce knee osteoarthritis trial heterogeneity: Phase 2 post-hoc data from Wnt pathway inhibitor SM04690	#P23
SM04690, a Wnt pathway inhibitor: Anti-inflammatory and cartilage protective effects in preclinical OA models	#P24
Results from a 52-week randomized, double-blind, placebo-controlled, phase 2 study of a novel, Wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment	#P40
Radiographic outcomes were concordant with pain and function response: Post-hoc analysis from a phase 2 study of SM04690, a Wnt pathway inhibitor for knee osteoarthritis treatment	#P41

Further details can be found on the BMJD website at <http://bmjd-congress.org/>. A copy of the presentation materials can be accessed by visiting the [Publications](#) section of the Samumed website following the conclusion of the conference.

About the 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)

BMJD is a comprehensive Congress fully devoted to clinical controversies in Bone, Muscle & Joint Diseases. The Congress addresses the most burning issues in the field and provides an effective forum for debating and discussing these issues. BMJD will tackle important questions in various sub-fields, including osteoarthritis, rheumatoid arthritis, inflammatory arthritis, pain, and related musculoskeletal diseases.

About SM04690

samumed

SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection and is being developed as a potential disease modifying drug for osteoarthritis (DMOAD). Vehicle-controlled preclinical data suggested that SM04690 has a dual mechanism of action with three effects on joint health – generation of cartilage, slowing down of cartilage breakdown, and reduction of inflammation. There are currently no approved disease modifying treatments for osteoarthritis. Additional information on Samumed’s SM04690 osteoarthritis program can be found here: <https://www.samumed.com/pipeline/detail.aspx?id=20>

About Samumed

Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative therapeutics and broad clinical pipeline at: <https://www.samumed.com/pipeline/default.aspx>

Corporate Contact:

Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200

Investor Contact:

Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742

Media Contact:

Josephine Belluardo, Ph.D.
LifeSci Public Relations
jo@lifescipublicrelations.com
646-751-4361